Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus Azacitidine
ASH 2025
Amer Zeidan, MBBS, of Yale School of Medicine, shares results from the phase I/II BEXMAB study, which examined the safety, tolerability and preliminary efficacy of bexmarilimab—a novel macrophage checkpoint inhibitor targeting Clever-1—in combination with the standard of care, azacitidine, in patients with higher-risk myelodysplastic syndromes (MDS), including those with TP53-mutated disease. (Abstract 236).
The ASCO Post Staff
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Abstract 683).
The ASCO Post Staff
Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. Researchers aimed to boost the bone marrow HPC niche and optimize mobilization in patients with multiple myeloma eligible for autologous hematopoietic cell transplant (Abstract 1050).
The ASCO Post Staff
Benjamin Diamond, MD, of the University of Miami, describes findings from the single-center phase II REKINDLE trial, which looked at the combination regimen of iberdomide, carfilzomib, daratumumab, and dexamethasone in patients with early relapsed/refractory multiple myeloma (Abstract 251).
The ASCO Post Staff
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516).
The ASCO Post Staff
Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, reviews data from three abstracts in myelodysplastic syndromes (MDS) presented at this year’s meeting: outcomes from the phase III VERONA trial of venetoclax with azacitidine vs placebo with azacitidine in patients with treatment-naive intermediate- and higher-risk MDS (Abstract 235); safety and efficacy results from a phase Ib trial of a dual IRAK1/4 inhibitor in patients with relapsed/refractory lower-risk MDS (Abstract 489); and results from the phase II ASTX030-01 trial, showing pharmacokinetic, efficacy, and safety data of oral ASTX030 in patients with MDS (Abstract 491).
